Next-generation sequencing in clinical oncology: next steps towards clinical validation

Bennett, Nigel C. and Farah, Camile S. (2014) Next-generation sequencing in clinical oncology: next steps towards clinical validation. Cancers, 6 4: 2296-2312. doi:10.3390/cancers6042296


 
Related Publications and Datasets
 
Author Bennett, Nigel C.
Farah, Camile S.
Title Next-generation sequencing in clinical oncology: next steps towards clinical validation
Journal name Cancers   Check publisher's open access policy
ISSN 2072-6694
Publication date 2014-01-01
Year available 2014
Sub-type Article (original research)
DOI 10.3390/cancers6042296
Open Access Status DOI
Volume 6
Issue 4
Start page 2296
End page 2312
Total pages 17
Place of publication Basel, Switzerland
Publisher M D P I AG
Language eng
Abstract Compelling evidence supports the transition of next generation sequencing (NGS) technology from a research environment into clinical practice. Before NGS technologies are fully adopted in the clinic, they should be thoroughly scrutinised for their potential as powerful diagnostic and prognostic tools. The importance placed on generating accurate NGS data, and consequently appropriate clinical interpretation, has stimulated much international discussion regarding the creation and implementation of strict guidelines and regulations for NGS clinical use. In the context of clinical oncology, NGS technologies are currently transitioning from a clinical research background into a setting where they will contribute significantly to individual patient cancer management. This paper explores the steps that have been taken, and those still required, for the transition of NGS into the clinical area, with particular emphasis placed on validation in the setting of clinical oncology.
Formatted abstract
Compelling evidence supports the transition of next generation sequencing (NGS) technology from a research environment into clinical practice. Before NGS technologies are fully adopted in the clinic, they should be thoroughly scrutinised for their potential as powerful diagnostic and prognostic tools. The importance placed on generating accurate NGS data, and consequently appropriate clinical interpretation, has stimulated much international discussion regarding the creation and implementation of strict guidelines and regulations for NGS clinical use. In the context of clinical oncology, NGS technologies are currently transitioning from a clinical research background into a setting where they will contribute significantly to individual patient cancer management. This paper explores the steps that have been taken, and those still required, for the transition of NGS into the clinical area, with particular emphasis placed on validation in the setting of clinical oncology.
Keyword Massively parallel sequencing
Next generation sequencing
Clinical oncology
Validation
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
Official 2015 Collection
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 21 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 27 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 22 Dec 2014, 23:32:26 EST by Roheen Gill on behalf of UQ Centre for Clinical Research